Business Context and Reporting Period
Calidi Biotherapeutics, Inc. (CLDI) filed this Form 8-K on March 8, 2024, reporting the entry into a Settlement Agreement with an investor. The agreement resolves disputes related to prior Supplemental Funding Agreements tied to the company's business combination consummated on September 12, 2023. The filing also notes an amendment to one of the resulting notes executed on March 11, 2024.
Key Financial Metrics and Obligations
This filing details the creation of new debt obligations rather than reporting operational financial results such as revenue or profit.
- Total New Debt: $3.5 million in convertible notes.
- Note 1: $2.0 million principal purchased by the investor for cash.
- Note 2: $1.5 million principal issued in consideration for settling claims.
- Interest Rate: 10.0% per annum, payable semiannually.
- Maturity Date: March 8, 2028.
- Prepayment: Permitted without penalty after 180 days or upon the effective date of a registration statement.
Material Changes and Settlement Details
The primary material change is the termination of all outstanding obligations under the Supplemental Funding Agreements (including a Non-Redemption Agreement and an OTC Equity Prepaid Forward Purchase Agreement) in exchange for the new Convertible Notes. The filing includes a mutual release of all claims between the Company and the investor.
An amendment to the $1.5 million note was executed on March 11, 2024, removing a condition that required the principal amount to be wired to the Company's bank account, reflecting that this note was issued as consideration for the settlement rather than a cash advance.
Terms, Conversion Features, and Risks
The Convertible Notes contain specific conversion and mandatory conversion provisions:
- Conversion Price: Initially set at 94% of the 10-day VWAP preceding execution. A reset price applies 30 days after the effective date of the registration statement (also 94% of 10-day VWAP).
- Mandatory Conversion Triggers:
- Completion of an SEC-registered offering of at least $8 million.
- Completion of a financing of at least $2 million with a non-affiliated purchaser at an effective price of at least 150% of the initial note conversion price.
- Regulatory Status: The securities were issued to an accredited investor under Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D.
The filing does not provide specific guidance on future revenue, cash flow, or operational outlook beyond the terms of this debt settlement.
Investor Verification Checklist
- Verify the current cash balance to assess the impact of the $2.0 million cash inflow from the investor.
- Review the full text of the Settlement Agreement (Exhibit 10.1) for any omitted material terms.
- Monitor the status of the registration statement for the underlying common stock, as this triggers prepayment rights and conversion price resets.
- Assess the dilution impact of the 94% conversion discount relative to the current trading price of CLDI common stock.
- Confirm the company's ability to service the 10% semiannual interest payments given its current liquidity position.